Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial

Conclusions: Our study show that nimotuzumab in addition to standard treatment is well tolerable and has increased survival in newly diagnosed GBM patients with EGFR positive expression.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Xiao-Jing Du, Xian-Ming Li, Lin-Bo Cai, Jian-Cong Sun, Si-Yang Wang, Xi-Cheng Wang, Xiao-Lin Pang, Mei-Ling Deng, Fang-Fang Chen, Zhi-Qiang Wang, Fu-Rong Chen, Hong-Hong Zhang, Hui-Yun Wang, Patricia Piedra, Zhong-Ping Chen, Jun Lin, Shao-Xiong Wu Tags: Research Paper Source Type: research